Depletion of CD34+ CD4+ cells in bone marrow from HIV-1-infected individuals.

Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.

Depletion of CD34+ CD4+ cells in bone marrow from HIV-1-infected individuals.

Biol Blood Marrow Transplant. 1999;5(3):162-72. Unique Identifier : AIDSLINE MED/99320133
Banda NK; Simon GR; Sipple JD; Terrell KL; Archer P; Shpall EJ; Akkina RK; Myers AM; Harrison GS; Department of Medicine, University of Colorado Health Sciences; Center, Denver 80262, USA. nirmal.banda@uchsc.edu

Abstract: Pancytopenia as a consequence of bone marrow abnormalities is commonly seen in HIV-infected individuals. To examine the effect that HIV-1 has on hematopoietic cells, we compared hematopoietic properties of bone marrow samples from HTV+ patients at various stages of disease with bone marrow samples from uninfected donors. While the absolute number of recovered CD34+ cells and the cloning efficiency of these cells did not differ significantly in HIV+ donors, the percentage of CD34+ CD4+ cells was significantly depleted in late-stage HIV+ patients. We observed a direct correlation between the numbers of CD34+ CD4+ cells in the bone marrow and the peripheral CD4 count. Further characterization of the CD34+ CD4+ subpopulation demonstrated that these cells expressed lower levels of HLA-DR on their surface compared with CD34+ CD4- cells, suggesting an immature phenotype. We also found evidence for expression of HIV-1 coreceptors CXCR-4 and CKR-5 message and protein in CD34+ bone marrow cells. While this finding suggested that hematopoietic cells might be susceptible to HIV infection at an early stage of maturation, thus affecting different cell lineages as they matured, we did not find any evidence for infection of HIV in these cells. These data suggest that HIV affects early hematopoietic progenitor cells either directly or indirectly, and in particular CD34+ CD4+ cells. This finding has important implications for disease pathogenesis and for application of gene therapy approaches that use CD34+ hematopoietic cells.

Keywords: JOURNAL ARTICLE Acquired Immunodeficiency Syndrome/IMMUNOLOGY Adult Antigens, CD34/*ANALYSIS Antigens, CD4/*ANALYSIS Bone Marrow Cells/*IMMUNOLOGY/METABOLISM/*PATHOLOGY Clone Cells Human HIV Infections/*IMMUNOLOGY HIV Seronegativity/IMMUNOLOGY HIV Seropositivity/IMMUNOLOGY HIV-1/GENETICS/IMMUNOLOGY/*ISOLATION & PURIF HLA-DR Antigens/BIOSYNTHESIS Middle Age Pancytopenia/*IMMUNOLOGY Receptors, CCR5/BIOSYNTHESIS Receptors, CXCR4/BIOSYNTHESIS Support, Non-U.S. Gov't Support, U.S. Gov't, P.H.S.
991230
A99C0997

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .